BioSpace News Archive

Lipocine Inc. today announced that it will present posters on LPCN 1148 and LPCN 1144 at the forthcoming European Association for the Study of the Liver (EASL) Congress 2023, to take place in Vienna, Austria, June 21 – 24, 2023.

VBI Vaccines Inc. today announced that an abstract highlighting T-cell responses and durability of immune responses following vaccination with VBI’s 3-antigen hepatitis B (HBV) vaccine, PreHevbrio™ [Hepatitis B Vaccine (Recombinant)], has been accepted for poster presentation at The International Liver Congress™ 2023 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place June 21-24.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced an agreement with a Blues plan in Hawaii.

Regen Lab, a Swiss commercial-stage medical technology company specializing in the research, development, registration, manufacturing and commercialization of proprietary tissue engineering products announces that its US subsidiary, RegenLab USA LLC, has entered into a collaboration agreement with Long Island University (LIU) and the Dassault Systèmes Group (3DS).

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of Bill Little as EVP of Corporate Development and Strategy and Andrew Taylor as CFO.

Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 28 June 2023, at 14:00 hours CEST at Advokatfirmaet CLP, Sommerrogata 13-15, 0255 Oslo.

MEKanistic Therapeutics Inc. announces the addition of Dr. Patricia LoRusso to its Scientific Advisory Board.

Precision Optics Corporation, Inc., a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced that as of June 2, 2023, it entered into a new $750,000 term loan with Main Street Bank.

Capricor Therapeutics today announced an upcoming Type-B clinical meeting with the U.S. Food and Drug Administration (FDA), planned in early Q3 2023.

In her late 50s, Marion’s doctor found a cancerous wart that required an intense six weeks of radiation therapy, coupled with chemotherapy.